Collaboration is core to our science and evident in everything we do – from the papers we publish, to the operational tone in our labs, to the partnerships we establish across industry and academia worldwide. And starting in 2019, AstraZeneca is doubling down on its commitment to collaboration – in a very big way.
In a new alliance, AstraZeneca is bringing together seven of the world’s foremost oncology medical centres to apply collective brainpower in expediting research in some of the hardest-to-treat cancers, each with strong translational research capabilities. They include:
- Institut Gustav Roussy (France)
- Johns Hopkins Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- Peter MacCallum Cancer Centre (Australia)
- Princess Margaret Cancer Center (Canada)
- Universidad de Navarra (Spain)
- Vall D’ Hebron Institute of Oncology (Spain)
How will this partnership accelerate innovation in the treatment of cancer? First and foremost, it will serve as a forum for scientific knowledge-sharing and investigation. The faster institutions can share findings, the faster these insights can be translated into practice-changing paradigms. These data and novel findings – what we learn in clinical trials – won’t just be sitting on the shelf; rather, they’ll be shared among partner institutions to be implemented as best practices for patients.
This partnership will also help AstraZeneca further optimise clinical trial design by learning from the ever-evolving science of cancer treatment.
As part of this initiative, AstraZeneca will be funding clinical and translational research proposals from the partner institutions, aimed at accelerating scientific research and optimising data collection and patient selection for clinical trials. We’ll work with our partners to ask the big questions, such as: How are specific pathways modified following standard-of-care cancer treatment? How can we identify which patients will be more likely to respond to specific therapies?
Today, there are more choices than ever to treat cancer. Still, more than eight million lives are lost each year to the disease. Working collaboratively, we have an enormous opportunity to shift the paradigm. As each day hundreds of patients walk through the doors of these seven partnering institutions, seeking and deserving treatments optimally targeted to their disease, this partnership will help us to expedite key clinical trials and accelerate the time it takes find the right treatment for the right patient.